Latest news with #FreseniusKabi
Yahoo
17-07-2025
- Business
- Yahoo
Fresenius Kabi Receives 2025 Premier Supplier Legacy Award
A Five-Time Winner, Fresenius Kabi is Cited for Operational Excellence LAKE ZURICH, Ill., July 17, 2025--(BUSINESS WIRE)--Fresenius Kabi, part of the global healthcare company Fresenius, and a leading provider of essential medicines and medical technologies, announced today it has received the 2025 Supplier Legacy Award from Premier, Inc., a leading technology-driven healthcare performance improvement company. This marks the fifth time since 2015 Premier has recognized Fresenius Kabi USA with this award for operational excellence. Fresenius Kabi was recognized for its long-standing support of Premier members through exceptional local customer service and engagement, value creation through clinical excellence and a commitment to lower costs. Supplier Legacy Award winners are selected by Premier member committees and have a tenure of more than three years as a Premier contracted supplier. "This award recognizes the commitment to service, innovation and collaboration by thousands of Fresenius Kabi employees from across our company," said Arun Verma, President, Fresenius Kabi Region U.S. and Member of the Executive Leadership Team, Fresenius Kabi AG. "It's especially gratifying to receive this award from a customer whose members make up more than 4,350 U.S. hospitals and health systems." "Fresenius Kabi supports Premier members by offering products and services that help improve costs, quality and operations – and deliver overall value," said Bruce Radcliff, Senior Vice President of Supply Chain at Premier. "We're honored to recognize Fresenius Kabi as a Supplier Legacy Award recipient." The Supplier Legacy Award recipients were honored during Premier's annual Breakthroughs Conference & Exhibition (July 15-17, 2025). Premier has awarded Fresenius Kabi its Supplier Legacy Award in 2015, 2017, 2018, 2021, and now in 2025. In 2024, Premier also awarded Fresenius Kabi its Trailblazer Award, one of Premier's highest honors, recognizing a national Premier-contracted supplier that delivers innovative and scalable methods and technologies to accelerate clinical evidence into real-world practice. About Fresenius Kabi As a global health care company, Fresenius Kabi is Committed to Life. The company's products, technologies, and services are used for the therapy and care of patients with critical and chronic conditions. With more than 41,000 employees and present in more than 100 countries, Fresenius Kabi's expansive product portfolio focuses on providing access to high-quality and lifesaving medicines and technologies. In Biopharma, Fresenius Kabi offers cutting-edge biosimilars for autoimmune diseases and oncology. With leading market positions in Clinical Nutrition, a broad portfolio of enteral and parenteral products makes a distinct difference in patients' nutritional status – notably as the only corporation offering both product groups. In MedTech, the company provides vital infusion pumps, cell and gene therapy devices, disposables, and more. Fresenius Kabi is a global leader in supplying blood collection bags and devices, supporting blood banks and health care facilities worldwide. The company's I.V. Generics and Fluids for infusion therapy help save millions of lives every year, in emergency medicine, surgery, oncology, and intensive care. Fresenius Kabi takes a holistic approach to health care and uniquely combines experience, expertise, innovation, and dedication – making a difference in the lives of 450 million patients annually. In line with the #FutureFresenius strategy, the company is developing, producing, and selling new products and technologies and aspires to expand its position as a leading global provider of therapies, improve patient care, generate sustainable value for stakeholders – shaping the future of health care. Fresenius Kabi is an operating company of the Fresenius Group, founded in 1912, along with Helios and Quirónsalud. As ONE team, the companies in the Fresenius Group are committed to providing lifesaving and life-changing health care solutions on a global scale. For more information, please visit To learn about U.S. career opportunities at Fresenius Kabi, visit us at and follow us on LinkedIn and Facebook. View source version on Contacts Media contact Matt Kuhn (847) Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Wire
17-07-2025
- Business
- Business Wire
Fresenius Kabi Receives 2025 Premier Supplier Legacy Award
LAKE ZURICH, Ill.--(BUSINESS WIRE)--Fresenius Kabi, part of the global healthcare company Fresenius, and a leading provider of essential medicines and medical technologies, announced today it has received the 2025 Supplier Legacy Award from Premier, Inc., a leading technology-driven healthcare performance improvement company. This marks the fifth time since 2015 Premier has recognized Fresenius Kabi USA with this award for operational excellence. Share This marks the fifth time since 2015 Premier has recognized Fresenius Kabi USA with this award for operational excellence. Fresenius Kabi was recognized for its long-standing support of Premier members through exceptional local customer service and engagement, value creation through clinical excellence and a commitment to lower costs. Supplier Legacy Award winners are selected by Premier member committees and have a tenure of more than three years as a Premier contracted supplier. 'This award recognizes the commitment to service, innovation and collaboration by thousands of Fresenius Kabi employees from across our company,' said Arun Verma, President, Fresenius Kabi Region U.S. and Member of the Executive Leadership Team, Fresenius Kabi AG. 'It's especially gratifying to receive this award from a customer whose members make up more than 4,350 U.S. hospitals and health systems.' 'Fresenius Kabi supports Premier members by offering products and services that help improve costs, quality and operations – and deliver overall value,' said Bruce Radcliff, Senior Vice President of Supply Chain at Premier. 'We're honored to recognize Fresenius Kabi as a Supplier Legacy Award recipient.' The Supplier Legacy Award recipients were honored during Premier's annual Breakthroughs Conference & Exhibition (July 15-17, 2025). Premier has awarded Fresenius Kabi its Supplier Legacy Award in 2015, 2017, 2018, 2021, and now in 2025. In 2024, Premier also awarded Fresenius Kabi its Trailblazer Award, one of Premier's highest honors, recognizing a national Premier-contracted supplier that delivers innovative and scalable methods and technologies to accelerate clinical evidence into real-world practice. About Fresenius Kabi As a global health care company, Fresenius Kabi is Committed to Life. The company's products, technologies, and services are used for the therapy and care of patients with critical and chronic conditions. With more than 41,000 employees and present in more than 100 countries, Fresenius Kabi's expansive product portfolio focuses on providing access to high-quality and lifesaving medicines and technologies. In Biopharma, Fresenius Kabi offers cutting-edge biosimilars for autoimmune diseases and oncology. With leading market positions in Clinical Nutrition, a broad portfolio of enteral and parenteral products makes a distinct difference in patients' nutritional status – notably as the only corporation offering both product groups. In MedTech, the company provides vital infusion pumps, cell and gene therapy devices, disposables, and more. Fresenius Kabi is a global leader in supplying blood collection bags and devices, supporting blood banks and health care facilities worldwide. The company's I.V. Generics and Fluids for infusion therapy help save millions of lives every year, in emergency medicine, surgery, oncology, and intensive care. Fresenius Kabi takes a holistic approach to health care and uniquely combines experience, expertise, innovation, and dedication – making a difference in the lives of 450 million patients annually. In line with the #FutureFresenius strategy, the company is developing, producing, and selling new products and technologies and aspires to expand its position as a leading global provider of therapies, improve patient care, generate sustainable value for stakeholders – shaping the future of health care. Fresenius Kabi is an operating company of the Fresenius Group, founded in 1912, along with Helios and Quirónsalud. As ONE team, the companies in the Fresenius Group are committed to providing lifesaving and life-changing health care solutions on a global scale. For more information, please visit To learn about U.S. career opportunities at Fresenius Kabi, visit us at and follow us on LinkedIn and Facebook.
Yahoo
17-07-2025
- Business
- Yahoo
Fresenius Kabi Receives 2025 Premier Supplier Legacy Award
A Five-Time Winner, Fresenius Kabi is Cited for Operational Excellence LAKE ZURICH, Ill., July 17, 2025--(BUSINESS WIRE)--Fresenius Kabi, part of the global healthcare company Fresenius, and a leading provider of essential medicines and medical technologies, announced today it has received the 2025 Supplier Legacy Award from Premier, Inc., a leading technology-driven healthcare performance improvement company. This marks the fifth time since 2015 Premier has recognized Fresenius Kabi USA with this award for operational excellence. Fresenius Kabi was recognized for its long-standing support of Premier members through exceptional local customer service and engagement, value creation through clinical excellence and a commitment to lower costs. Supplier Legacy Award winners are selected by Premier member committees and have a tenure of more than three years as a Premier contracted supplier. "This award recognizes the commitment to service, innovation and collaboration by thousands of Fresenius Kabi employees from across our company," said Arun Verma, President, Fresenius Kabi Region U.S. and Member of the Executive Leadership Team, Fresenius Kabi AG. "It's especially gratifying to receive this award from a customer whose members make up more than 4,350 U.S. hospitals and health systems." "Fresenius Kabi supports Premier members by offering products and services that help improve costs, quality and operations – and deliver overall value," said Bruce Radcliff, Senior Vice President of Supply Chain at Premier. "We're honored to recognize Fresenius Kabi as a Supplier Legacy Award recipient." The Supplier Legacy Award recipients were honored during Premier's annual Breakthroughs Conference & Exhibition (July 15-17, 2025). Premier has awarded Fresenius Kabi its Supplier Legacy Award in 2015, 2017, 2018, 2021, and now in 2025. In 2024, Premier also awarded Fresenius Kabi its Trailblazer Award, one of Premier's highest honors, recognizing a national Premier-contracted supplier that delivers innovative and scalable methods and technologies to accelerate clinical evidence into real-world practice. About Fresenius Kabi As a global health care company, Fresenius Kabi is Committed to Life. The company's products, technologies, and services are used for the therapy and care of patients with critical and chronic conditions. With more than 41,000 employees and present in more than 100 countries, Fresenius Kabi's expansive product portfolio focuses on providing access to high-quality and lifesaving medicines and technologies. In Biopharma, Fresenius Kabi offers cutting-edge biosimilars for autoimmune diseases and oncology. With leading market positions in Clinical Nutrition, a broad portfolio of enteral and parenteral products makes a distinct difference in patients' nutritional status – notably as the only corporation offering both product groups. In MedTech, the company provides vital infusion pumps, cell and gene therapy devices, disposables, and more. Fresenius Kabi is a global leader in supplying blood collection bags and devices, supporting blood banks and health care facilities worldwide. The company's I.V. Generics and Fluids for infusion therapy help save millions of lives every year, in emergency medicine, surgery, oncology, and intensive care. Fresenius Kabi takes a holistic approach to health care and uniquely combines experience, expertise, innovation, and dedication – making a difference in the lives of 450 million patients annually. In line with the #FutureFresenius strategy, the company is developing, producing, and selling new products and technologies and aspires to expand its position as a leading global provider of therapies, improve patient care, generate sustainable value for stakeholders – shaping the future of health care. Fresenius Kabi is an operating company of the Fresenius Group, founded in 1912, along with Helios and Quirónsalud. As ONE team, the companies in the Fresenius Group are committed to providing lifesaving and life-changing health care solutions on a global scale. For more information, please visit To learn about U.S. career opportunities at Fresenius Kabi, visit us at and follow us on LinkedIn and Facebook. View source version on Contacts Media contact Matt Kuhn (847)
Yahoo
02-07-2025
- Business
- Yahoo
mAbxience Announces European Commission Approval of Denosumab Biosimilars
MADRID, July 2, 2025 /PRNewswire/ -- mAbxience, a Fresenius Kabi majority-owned group with partial ownership from Insud Pharma, is pleased to announce that the European Commission has granted approval for its denosumab biosimilars Denbrayce® and Izamby®. This approval follows a positive recommendation from the Committee for Medicinal Products for Human Use (CHMP) and represents a major milestone in mAbxience's mission to provide high-quality, accessible, and affordable therapies worldwide. Denbrayce®, referencing Amgen's Xgeva®, is indicated for the prevention of skeletal-related events in adults with advanced malignancies involving bone, as well as for the treatment of adults and skeletally mature adolescents with giant cell tumor of bone. Izamby®, referencing Amgen's Prolia®, is indicated for the treatment of osteoporosis in postmenopausal women and in men at increased risk of fractures, a condition that causes bones to become weak and more prone to breaking. "This approval is a testament to mAbxience's dedication to scientific excellence and our commitment to broadening access to essential biologic therapies," said Jurgen Van Broeck, CEO of mAbxience. "We are proud to contribute to reducing the burden of osteoporosis, cancer-related bone conditions, and rare bone diseases in Europe. This milestone brings us one step closer to ensuring that more patients across Europe can benefit from high-quality, affordable treatment options." Denosumab is a human monoclonal antibody that works by inhibiting the receptor activator of nuclear factor kappa-B ligand (RANKL), thereby preventing the development of osteoclasts, the cells responsible for bone breakdown. It is a well-established treatment for osteoporosis, treatment-induced bone loss, bone metastases, and giant cell tumor of bone. With the approval of these biosimilars mAbxience further demonstrates its expertise in the development and production of biosimilars, reinforcing its contribution to improving patient access to life-changing therapies and supporting the sustainability of healthcare systems across Europe. This approval marks another important step in mAbxience's mission to provide affordable, accessible and life-changing therapies worldwide. With a robust pipeline and a growing network of partners, mAbxience continues to enhance patient access to advanced treatments while supporting healthcare systems in managing the rising costs of biologic medicines. About mAbxience mAbxience is a Spanish-based company specializing in the development, production, and commercialization of biopharmaceuticals. In August 2022, Fresenius Kabi and Insud Pharma entered into an agreement whereby Fresenius Kabi, an operating company of Fresenius, acquired a majority stake of mAbxience, making it a global, vertically integrated biotechnology company. With over a decade of expertise, our mission is clear: to provide accessible, affordable medicines across the globe, aiming to enhance the quality of life by ensuring universal access to high-caliber medicines. With two market-approved products and a robust pipeline in development, we have established a B2B presence in over 100 markets. Alongside this, we have formed a network with more than 30 partners and built a dedicated team of over 1,000 professionals. Our three multi-product facilities, located in Europe and South America, have obtained GMP approval from esteemed regulatory bodies, including the FDA, EMA, and others. Furthermore, as a global biopharmaceutical expert, mAbxience specializes in Contract Development and Manufacturing Organization services (CDMO), utilizing advanced technology and innovative platforms to deliver integrated manufacturing solutions. For more insights into mAbxience, our biosimilars and CDMO business, please visit our website ( or connect with us on LinkedIn. Photo: View original content to download multimedia: SOURCE mAbxience Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Cision Canada
04-06-2025
- Business
- Cision Canada
Fresenius Kabi Canada launches Iodixanol Injection 270 & 320 - the first and only generic to Visipaque® in Canada Français
Fresenius Kabi received Health Canada's Notice of Compliance (NOC) approval for Iodixanol injection on December 17 for both intravenous and intra-arterial administration With the launch of Iodixanol injection, Fresenius Kabi Canada is looking to expand into the contrast media space, with a commitment to bring more treatment options for patients requiring diagnostic imaging Iodixanol injection is approved for all indications of the reference product Visipaque ® and available immediately TORONTO, June 4, 2025 /CNW/ - Fresenius Kabi Canada, part of Fresenius group, announced the recent launch of Iodixanol Injection 270 and 320 for both the intravenous and intra-arterial administrations. Iodixanol Injection is a contrast agent with uses in angiocardiography, arteriography, CT scanning of head and body, excretory urography and venography. Health Canada's NOC approval of Iodixanol Injection 270 & 320 was granted on December 17, 2024, and is based on a thorough evaluation of a comprehensive data package demonstrating pharmaceutical equivalence to the reference drug Visipaque ®. With this approval, Fresenius Kabi is building its footprint in the contrast media space in Canada, following recent successful launches of contrast media products in the United States. Expanding a strong presence into the imaging agent space is a substantial cornerstone of Fresenius Kabi's Vision 2026 and the #FutureFresenius strategy. "Fresenius Kabi's Iodixanol Injection will be the first generic for injectable iodinated contrast media on the market in Canada," said Lee Fulford Sr. Marketing Manager, Specialty Pharma at Fresenius Kabi Canada. "With this launch we are committed to bringing value to Canadians, by lowering the cost as well as adding supply stability to a market that has had devastating shortages historically." In recent years global shortages of iodinated contrast media have led to Canadian healthcare agencies having to adopt strategies to mitigate shortages including selecting which patients would get contrast and reducing dosages where possible 1. Iodixanol injection was added in June 2022 to Health Canada's tier 3 drug shortage list. Tier 3 drug shortages are those likely to have the greatest potential impact to the Health Care system 2. "We are proud to be introducing an affordable alternative Iodixanol diagnostic option which will strengthen Canada's supply for this critical agent. This launch underscores our commitment to enhancing patient care through accessible therapies," said Martin Willner, General Manager, Fresenius Kabi Canada. About Fresenius Kabi: Fresenius Kabi, an operating company of Fresenius, specializes in clinical nutrition, medical technologies, and I.V. generics and fluids for the therapy and care of critically and chronically ill patients. With more than 41,000 employees and present in over 100 countries, Fresenius Kabi's expansive product portfolio focuses on providing access to high-quality and lifesaving medicines and technologies. About Iodixanol Injection Iodixanol injection is a non-ionic radiographic contrast medium with uses in angiocardiography, arteriography, CT scanning of head and body, excretory urography and venography. The lower osmolality of Iodixanol Injection (which is isotonic with blood) compared with conventional contrast media of similar iodine concentration can be expected to cause fewer and less severe osmolality-related disturbances, specifically, less pain, heat and burning sensation, upon injection 3. Fresenius Kabi's Iodixanol Injection is free of preservatives and comes in a polymer bottle. The container closure is not made with natural rubber latex. Fresenius Kabi Iodixanol Injection is currently available in six presentations for intra-arterial and intravenous procedures: 270 mg Iodine per mL: 100 mL polymer bottle 150 mL polymer bottle 320 mg Iodine per mL: 50 mL polymer bottle 100 mL polymer bottle 150 mL polymer bottle 200 mL polymer bottle For more information, please visit This release contains forward-looking statements that are subject to various risks and uncertainties. Future results could differ materially from those described in these forward-looking statements due to certain factors, e.g., changes in business, economic and competitive conditions, regulatory reforms, results of clinical trials, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings, and the availability of financing. Fresenius Kabi does not undertake any responsibility to update the forward-looking statements in this release. Management Board: Pierluigi Antonelli (Chairman), Marc Crouton, Andreas Duenkel, Dr. Christian Hauer, Dr. Marc-Alexander Mahl, Dr. Sang-Jin Pak Chairman of the Supervisory Board: Wolfgang Kirsch Registered Office: Bad Homburg, Germany Commercial Register: Amtsgericht Bad Homburg - HRB 11654
